Immunological features of pneumocystis infection in humans

Pneumocystis Pneumonia: Third Edition, Revised and Expanded

Volumn , Issue , 2004, Pages 451-478

  Walzer, Peter D ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85057286207     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (209)

1. Walzer PD. Pneumocystis carinii. In Mandell GL, Bennett JE, Dolin P, Eds. Principles and Practice of Infections Diseases. New York: Churchill Livingstone, 2000:2781-2795.
2. Armstrong MYK, Cushion MT. Animal models. In Walzer PD, Ed. Pneumocystis carinii Pneumonia, Marcel Dekker. 1994:181-222.
3. Walzer PD. Immunological features of Pneumocystis carinii infection in humans. Clin Diagn Lab Immunol 1999; 6:149-155.
4. Stringer JR, Beard CB, Miller RF, Wakefield AE. A new name (Pneumocystis jiroveci) for Pneumocystis from humans. Emerg Infect Dis 2002; 8:891-896.
5. Gigliotti F. Host species-specific antigenic variation of a mannonsylated surface glycoprotein of Pneumocystis carinii. J Infect Dis. 1992; 165:329-336.
6. Lundgren B, Lipchik GY, Kovacs JA. Purfication and characterization of a major human Pneumocystis carinii surface antigen. J Clin Invest 1991; 87:163-170.
7. Linke MJ, Cushion MT, Walzer PD. Properties of the major rat and human Pneumocystis carinii antigens. Infect Immun 1989; 57:1547-1555.
8. Haidaris CG, Medzihradsky OF, Gigliotti F, et al. Molecular characterization of mouse Pneumocystis carinii surface glycoprotein A. DNA Res 1998; 5:77-85.
9. Pottratz ST, Paulsrud J, Smith JS, Martin WJ. Pneumocystis carinii attachment to cultured lung cells by Pneumocystis g p 120, a fibronectin binding protein. J Clin Invest 1991; 88:403-407.
10. Limper AH. Vitronectin binds to Pneumocystis carinii and mediates organism attachment to cultured lung epithelial cells. Infect Immun 1993; 61:4302-4309.
11. Ezekowitz RAB, Williams DJ, Koziel H, et al. Uptake of Pneumocystis carinii mediated by the macrophage mannose receptor. Nature 1991; 351:155-158.
12. Fishman JA, et al. The effects of extracellular matrix (ECM) proteins on the attachment of Pneumocystis carinii to lung cell lines in vitro. J Protozool 1991; 38: 34S-37S.
13. Neese LW, Standing JE, Olson EJ, Castro M, Limper AH. Vitronectin, fibronectin, and gp120 antibody enhance macrophage release of TNF-alpha in response to Pneumocystis carinii. J Immunol 1994; 152:4549-4556.
14. O’Riordan DM, Standing JE, Kwon KY, Chang D, Crouch EC, Limper AH. Surfactant protein D interacts with Pneumocystis carinii and mediates organism adherence to alveolar macrophages. J Clin Invest 1995; 95:2699-2710.
15. O’Riordan DM, Standing JE, Limper AH. Pneumocystis carinii glycoprotein A binds macrophage mannose receptors. Infect Immun 1995; 63:779-784.
16. McCormack FX, Festa AL, Andrews RP, Linke M, Walzer PD. The carbohydrate binding domain of surfactant protein A mediates binding to the major surface glycoprotein of Pneumocystis carinii. Biochemistry 1997; 36:8092-8099.
17. Benfield TL, Lundgren B, Levine SJ, Kronborg G, Shelhamer JH, Lundgren JD. The major surface glycoprotein of Pneumocystis carinii induces release and gene expression of interleukin-8 and tumor necrosis factor alpha in monocytes. Infect Immun 1997; 65:4790-4794.
18. Walzer PD, Linke MJ. A comparison of the antigenic characteristics of rat and human Pneumocystis carinii by immunoblotting. J Immunol 1987; 138:2257-2265.
19. Kovacs JA, Swann JC, Shelhammer J, et al. Monoclonal antibodies to Pneumocystis carinii: identification of specific antigens and characterization of antigenic differences between rat and human isolates. J Infect Dis 1989; 159:60-70.
20. Linke MJ, Sunkin SM, Andrews RA, Stringer JR, Walzer PD. Expression, structure, and location of epitopes of the major surface glycoprotein Pneumocystis carinii. Clin Diagn Lab Immunol 1998; 5:50-57.
21. Theus SA, Linke MJ, Andrews RP, Walzer PD. Proliferative response and cytokine production to a major surface glycoprotein of Pneumocystis carinii. Infect Immun 1993; 61:4703-4709.
22. Theus SA, Smulian AG, Sullivan D, Walzer PD. Cytokine responses to the native and recombinant forms of the major surface glycoprotein of Pneumocystis carinii. Clin Exp Immunol 1997; 109:255-260.
23. Theus SA, Sawhney N, Smulian AG, Walzer PD. Proliferation and cytokine responses of human T lymphocytes isolated from HIV patients to the major surface glycoprotein of Pneumocystis carinii. J Infect Dis 1998; 177:238-241.
24. Gigliotti F, Hughes WT. Passive immunoprophylaxis with specific monoclonal antibody confers partial protection against Pneumocystis carinii pneumonitis in animal models. J Clin Invest 1988; 81:1666-1668.
25. Gigliotti F, Haidaris CG, Wright TW, Harmsen AG. 2002. Passive intranasal monoclonal antibody prophylaxis against murine Pneumocystis carinii pneumonia. Infect Immun 70:1069-1074.
26. Roths JB, Sidman CL. Both immunity and hyperresponsiveness to Pneumocystis carinii result from transfer of CD4 + but not CD8 + T cells into severe combined immunodeficiency mice. J Clin Invest 1992; 90:673-678.
27. Roths JB, Sidman CL. Single and combined humoral and cell-mediated immunotherapy of Pneumocystis carinii pneumonia in immunodeficient SCID mice. Infect Immun 1993; 61:1641-1649.
28. Theus SA, Andrews RP, Stelle P, Walzer PD. Adoptive transfer of lymphocytes sensitized to the major surface glycoprotein confers protection in the rat. J Clin Invest 1995; 95:2587-2593.
29. Theus SA, Walzer PD. Adoptive transfer of specific lymphocyte populations sensitized to the major surface glycoprotein of Pneumocystis carinii decreases organism burden while increasing survival rate in the rat. J Eukaryot Microbiol 1997; 44: 23-24.
30. Theus SA, Smulian AG, Steele P, Linke MJ, Walzer PD. Immunization with the major surface glycoprotein of Pneumocystis carinii elicits a protective response. Vaccine 1998; 16:1149-1157.
31. Gigliotti F, Wiley JA, Harmsen AG. Immunization with Pneumocystis carinii gpA is immunogenic but not protective in a mouse model of P. carinii pneumonia. Infect Immun 1998; 66:3179-3182.
32. Lasbury ME, Angus CW, Klivington D, Durant PJ, Bartlett MS, Smith JW, Lee CH. Recombinant major surface glycoprotein of Pneumocystis carinii elicits a specific immune response but is not protective in immunosuppressed rats. J Eukaryot Microbiol 1999; 46:136S-137S.
33. Kovacs JA, Powell F, Edman JC, Lundgren B, Martinez A, Drew B, Angus CW. Multiple genes encode the major surface glycoprotein of Pneumocystis carinii. J Biol Chem 1993; 268:6034-6040.
34. Smulian AG, Keely SP, Sunkin SM, Stringer JR. Genetic and antigenic variation in Pneumocystis carinii organisms: tools for examining the epidemiology and pathogenesis of infection. J Lab Clin Med 1997; 130:461-468.
35. Stringer JR, Keely SP. Genetics of surface antigen expression in Pneumocystis carinii. Infect Immun 2001; 69:627-639.
36. Sunkin SM, Linke MJ, Mc Cormack FX, Walzer PD, Stringer JR. Identification of a putative precursor to the major suface glycoprotein of Pneumocystis carinii. Infect Immun 1998; 66:741-746.
37. Kutty G, Ma L, Kovacs JA. Characterization of the expression site of the major surface glycoprotein of human-derived Pneumcoystis carinii. Mol Microbiol 2001; 42:183-193.
38. Linke MJ, Smulian AG, Stringer JR, Walzer PD. Characterization of multiple unique cDNAs encoding the major surface glycoprotein of rat-derived Pneumocystis carinii. Parasitol Res 1994; 80:478-486.
39. Angus CW, Tu A, Vogel P, Qin M, Kovacs JA. Expression of variants of the major surface glycoprotein of Pneumocystis carinii. J Exp Med 1996; 183:1229-1234.
40. Gigliotti F, Garvy BA, Harmsen AG. Antibody-mediated shift in the profile of glycoprotein A phenotypes observed in a mouse model of Pneumocystis carinii pneumonia. Infect Immun 1996; 64:1892-1899.
41. Lugli EB, Bampton ET, Ferguson DJ, Wakefield AE. Cell surface protease PRT1 identified in the fungal pathogen Pneumocystis carinii. Mol Microbiol 1999; 31: 1723-1733.
42. Russian DA, Andrawis-Sorial V, Goheen MP, Edman JC, Vogel P, Turner RE, Klivington DL, Angus CW, Kovacs JA. Characterization of a multicopy family of genes encoding a surface-expressed serine endoprotease in rat Pneumocystis carinii. Proc Assoc Am Physicians 1999; 111:347-356.
43. Schaffzin JK, Sunkin SM, Stringer JR. A new family of Pneumocystis carinii genes related to those encoding the major surface glycoprotein. Curr Genet 1999; 35: 134-143.
44. Lee LH, Gigliotti F, Wright TW, Simpson-Haidaris PJ, Weinberg GA, Haidaris CG. Molecular characterization of KEX1, a kexin-like protease in mouse Pneumocystis carinii. Gene 2000; 242:141-150.
45. Kutty G, Kovacs JA. A single copy gene encodes Kex 1, a serine endoprogtease of Pneumocystis jiroveci. Infect Immun 2003; 71:571-574.
46. Smulian AG, Stringer JR, Linke MJ, Walzer PD. Isolation and characterization of a recombinant immunoreactive antigen of Pneumocystis carinii. Infect Immun 1992; 60:907-915.
47. Smulian AG, Theus SA, Denko N, Walzer PD, Stringer JR. A 55 kDa antigen of Pneumocystis carinii: analysis of the cellular immune response and characterization of the gene. Mol Microbiol 1993; 7:745-753.
48. Theus SA, Sullivan DW, Walzer PD, Smulian AG. Cellular immune responses to a 55-kilodalton recombinant Pneumocystis carinii antigen. Infect Immun 1994; 62: 3479-3484.
49. Broomall KR, Morris RE, Walzer PD, Smulian AG. Zymolyase treatment exposes p55 antigen of Pneumocystis carinii. J Eukaryot Microbiol 1998; 45:284-289.
50. Smulian AG, Sullivan DW, Theus SA. Immunization with recombinant Pneumocystis carinii p55 antigen provides partial protection against infection: characterization of epitope recognition associated with immunization. Microbes Infect 2000; 2:127-136.
51. Smulian AG, Linke MJ, Baughman RP, Dohn M, Frame PT, Whit M, Walzer PD. 1994. Analysis of Pneumocystis carinii antigens in bronchoalveolar lavage fluid in patients with pneumocystosis. AIDS 1994; 8:1555-1562.
52. Sethi KK. 1990. Application of immunoblotting to detect soluble Pneumocystis carinii antigen(s) in bronchoalveolar lavage of patients with Pneumocystis carinii and AIDS. J Clin Pathol 1990; 43:584-586.
53. Goldenberg DM, Sharkey RM, Levine GM, Hansen HJ, Swayne LC, Conte PJ, Linke MJ, Smulian AG, Walzer PD. Immunoscintigraphy of Pneumocystis carinii pneumonia in AIDS patients. J Nucl Med 1994; 35:1028-1034.
54. Kroe DM, Kirsch CM, Jensen WA. Diagnostic strategies for Pneumocystis carinii pneumonia. Semin Respir Infect 1997; 12:70-78.
55. Walzer PD, Kim CK, Cushion MT. Pneumocystis carinii. In Walzer PD, Genta RM, Eds. Parastic Infections in the Compromised Host. New York: Marcel Dekker, 1989:83-178.
56. Esolen LM, Fasano MB, Flynn J, et al. Brief report: Pneumocystis carinii osteomyelitis in a patient with common variable immunodeficiency. N Engl J Med 1992; 326:909-1001.
57. Marcotte H, Levesque D, Delanay K, et al. Pneumocystis carinii infection in transgenic B cell-deficient mice. J Infect Dis 1996; 173:1034-1037.
58. Walzer PD, Runck J, Steele P, et al. Immunodeficient and immunosuppressed mice as models to test anti-Pneumocystis carinii drugs. Antimicrob Agents Chemother 1997; 41:251-258.
59. Lee M, Cho SR, Park YK, Choi MH, Hong ST. The effect of heterogeneous hyperimmune IgG antibody on prophylaxis and treatment of Pneumocystis carinii infection in rats. Korean J Parasitol 1998; 36:127-132.
60. Bartett MS, Angus WC, Shaw MM, Durant PJ, Lee CH, Pascale JM, Smith JW. Antibody to Pneumocystis carinii protects rats and mice from developing pneumonia. Clin Diagn Lab Immun 1998; 5:74-77.
61. Harmsen AG, Chen W, Gigliotti F. Active immunity to Pneumocystis carinii reinfection in T-cell-depleted mice. Infect Immun 1995; 63:2391-2395.
62. Gigliotti F, Wiley JA, Harmsen AG. Immunization with Pneumocystis carinii gpA is immunogenic but not protective in a mouse model of P. carinii pneumonia. Infect Immun 1998; 66:3179-3182.
63. Pascale JM, Shaw MM, Durant PJ, Amador AA, Bartlett MS, Smith JW, Gregory RL, McLaughlin GL. Intranasal immunization confers protection against murine Pneumocystis carinii lung infection. Infect Immun 1999; 67:805-809.
64. Garvy BA, Wiley JA, Gigliotti F, Harmsen AG. Protection against Pneumocystis carinii pneumonia by antibodies generated from either T helper 1 or T helper 2 responses. Infect Immun 1997; 65:5052-5056.
65. Zheng M, Shellito JE, Marrero L, Zhong Q, Julian S, Ye P, Wallace V, Schwarzenb-erger P, Kolls JK. CD4 + T cell-independent vaccination against Pneumocystis carinii in mice. J Clin Invest 2001; 108:1469-1474.
66. Masur H, Jones TC. The interaction in vitro of Pneumocystis carinii with macrophage and L-cells. J Exp Med 1978; 147:157-170.
67. Walzer PD, Rutledge ME. Humoral immunity in experimental Pneumocystis carinii pneumonia. I. Systemic and local antibody responses in rats. J Lab Clin Med 1981; 97:820-833.
68. Walzer PD, Rutledge ME. Serum antibody responses to Pneumocystis carinii among different strains of normal and athymic (nude) mice. Infect Immun 1982; 35: 620-626.
69. Icenhour CR, Rebholz SL, Collins MS, Cushion MT. Widespread occurrence of Pneumocystis carinii in commercial rat colonies detected using targeted PCR and oral swabs. J Clin Microbiol 2001; 35:3437-3441.
70. Smulian AG, Walzer PD. Serological studies of Pneumocystis carinii infection. In Walzer PD, Ed. Pneumocystis carinii Pneumonia, Marcel Dekker. 1994:141-151.
71. Smulian AG, Sullivan D, Linke MJ, Halsey N, Quinn T, MacPhail AP, Kreiss J, Bryan RT, Hernandez MA, Hong ST, Walzer PD. Geographic variation in the humoral response to Pneumocystis carinii. J Infect Dis 1993; 167:1243-1247.
72. Lundgren B, Kovacs JA, Mathiesen L, Nielsen JO, Lundgren JD. IgM response to a human Pneumocystis carinii surface antigen in HIV-infected patients with pulmonary symptoms. Scand J Infect Dis 1993; 25:515-520.
73. Lundgren B, Lebech M, Lind K, Nielsen JO, Lungren JD. Antibody response to a major human Pneumocystis carinii surface antigen in patients without evidence of immunosuppression and in patients with suspected atypical pneumonia. Eur J Clin Microbiol Infect Dis 1993; 12:105-109.
74. Buhl L, Settnes OP, Andersen PL. Antibodies to Pneumocystis carinii in Danish blood donors and AIDS patients with and with Pneumocystis carinii pneumonia. APMIS 1993; 101:707-710.
75. Leigh TR, Millett MJ, Jameson B, Collins JV. Serum titres of Pneumocystis carinii antibody in health care workers caring for patients with AIDS. Thorax 1993; 48: 619-621.
76. Elvin K, Bjorkman A, Heurlin N, Eriksson BM, Barkholt L, Linder E. Seroreactivity to Pneumocystis carinii in patients with AIDS versus other immunosuppressed patients. Scand J Infect Dis 1994; 26:33-40.
77. Chen Y, Mei Q, Liu Y, Wang Q. Laboratory and clinical study on Pneumocystis carinii. II. Immunoblot analysis for detection of anti-Pneumocystis carinii antibodies in the sera from healthy blood donors. Zhongguo Ji Sheng Chong Bing Za Zhi 1994; 12:115-118.
78. Moon HN, Hong ST, Lee SH. Serologic response of normal Korean children to Pneumocystis carinii as observed by immunoblot. Korean J Parasitol 1995; 33: 101-106.
79. Lidman C, Olsson M, Bjorkman A. No evidence of of nosocomial Pneumocystis carinii infection via hospital personnel. Scand J Infect Dis 1997; 29:63-64.
80. Lundgren B, Elvin K, Rothman LP, Ljungstrom I, Lidman C, Lundgren JD. Transmission of Pneumocystis carinii from patients to hospital staff. Thorax 1997; 52: 422-224.
81. Laursen AL, Andersen PL. Low levels of IgG antibodies against Pneumocystis carinii among HIV-infected patients. Scand J Infect Dis 1998; 30:495-499.
82. Mei Q, Turner RE, Sorial V, Klivington D, Angus CW, Kovacs JA. Characterization of major surface glycoprotein genes of human Pneumocystis carinii and high-level expression of a conserved region. Infect Immun 1998; 66:4268-4273.
83. Park HY, Lee SU, Chae SW, Huh S, Yu JR, Kim J, Hong ST. Variation of antigenicity and serological reaction to Pneumocystis carinii in Korea. Korean J. Parasitol 1999; 37:109-115.
84. Vargas SL, Hughes WT, Santolaya ME. Search for primary infection by Pneumocystis carinii in a cohort of normal, healthy infants. Clin Infect Dis 2001; 32: 855-861.
85. Daly K, Tanka R, Linke MJ, Obert R, Thullen T, Hui M, Smulian AG, Fichtenbaum C, Walzer PD. Serologic responses to epitopes of the major surface glycoprotein of Pneumocystis jiroveci differ in human immunodeficiency virus-infected and uninfected persons. J Infect Dis 2002; 186:644-651.
86. Daly KR, Koch J, Levin L, Walzer PD. Enzyme-linked immunosorbent assay and serologic responses to Pneumocystis jiroveci. Emerg Infect Dis 2004; 10:848-854.
87. Meuwissen JHE, Kagan IA, Leeuwenberg ADE, Beckers PJA, Sieben M. Parasitologic and serologic observations of infection with Pneumocystis in humans. J Infect Dis 1977; 136:43-49.
88. Pifer LL, Hughes WT, Stago S, Woods D. Pneumocystis carinii infection: evidence for high prevalence in normal and immunosuppressed children. Pediatrics 1978; 61:35-41.
89. Peglow SL, Smulian GA, Linke MJ, Crisler J, Phair JWM, Gold J, Armstrong D, Walzer PD. Serologic responses to specific Pneumocystis carinii antigens in health and disease. J Infect Dis 1990; 161:296-306.
90. Wakefield AE, Stewart TJ, Moxon ER, Marsh K, Hopkin JN. Infection with Pneumocystis carinii is prevalent in healthy Gambian children. Trans R Soc Trop Med Hyg 1990; 84:800-802.
91. Lundgren B, Lundgren JD, Nielsen T, Mathiesen L, Nielsen JO, Kovacs JA. Antibody responses to a major Pneumocystis carinii antigen in human immunodeficiency virus-infected patients with and without P. carinii pneumonia. J Infect Dis 1992; 165:1151-1155.
92. Giron JA, Martinez S, Walzer PD. Should inpatients with Pneumocystis carinii be isolated? Lancet 1982; 2:46.
93. Ruebush TK, Weinstein RA, Baehner RL, Wolff D, Barlett M, Gonzales-Crussi F, Sulzer A, Schultz MG. An outbreak of Pneumocystis pneumonia in children with acute lymphocytic leukemia. Am J Dis Child 1978; 132:143-148.
94. Singer C, Armstrong D, Rosen PP, Schottenfeld D. Pneumocystis carinii pneumonia: a cluster of eleven cases. Ann. Intern. Med 1975; 82:772-777.
95. Burns SM, Read JA, Yap PL, Brettle RP. Reduced concentrations of IgG antibodies to Pneumocystis carinii in HIV-infected patients during active Pneumocystis carinii infection and the possibility of passive immunization. J Infect 1990; 20:33-39.
96. Hofmann G, Odum N, Platz P, Ryder LP, Svejgaard A, Nielsen PB, Holten-Ander-sen W, Gerstoft J, Nielsen JO, Mojon M. Humoral responses to Pneumocystis carinii in patients with acquired immunodeficiency syndrome and in immunocompromised homosexual men. J Infect Dis 1985; 152:838-840.
97. Hofmann B, Nielsen PB, Odum N, Gerstoft J, Platz P, Ryder LP, Poulsen A, Mathiesen L, Dickmeiss E, Norrild B, Andersen HK, Westergaard BF, Nielsen CM, Holten-Andersen W, Mojon M, Nielsen JO, Svejaard A. Humoral and cellualr responses to Pneumocystis carinii, CMV, and herpes simplex in patients with AIDS and in controls. Scand J Infect Dis 1988; 20:389-394.
98. Pifer LL, Niell HB, Langdon SB, et al. Evidence of depressed humoral immunity to Pneumocystis carinii in homosexual males, commercial plasma donors, and patients with acquired immunodeficiency syndrome. J Clin Microbiol 1987; 25: 991-995.
99. Laursen AL, Jensen BN, Andersen PL. Local antibodies against Pneumocystis carinii in bronchoalveolar lavage fluid. Eur Respir J 1994; 7:679-685.
100. Jalil A, Moja C, Lambert M, et al. Decreased production of local immunoglobulin A to Pneumocystis carinii in bronchoalveolar lavage fluid of huan immunodeficiency virus-positive patients. Infect Immun 2000; 68:1054-1060.
101. Rankin JA, Walzer PD, Dwyer JM, Schraeder CE, Enriquez R, Merrill WW. Immunologic alterations in bronchoalveolar lavage fluid in the acquired immune deficiency syndrome (AIDS). Am Rev Respir Dis 1983; 128:189-194.
102. Garbe TR, Stringer JR. Molecular characterization of clustered variants of genes encoding major surface antigens of human Pneumocystis carinii. Infect Immun 1994; 62:3092-3101.
103. Walzer PD, Schnelle V, Armstrong D, Rosen PP. The nude mouse: a new experimental model for Pneumocystis carinii infection. Science 1977; 197:177-179.
104. Walzer PD, Kim CK, Linke MJ, et al. Outbreaks of Pneumocystis carinii pneumonia in colonies of immunodeficient mice. Infect Immun 1989; 57:62-70.
105. Hanano R, Reifenberg K, Stefan H, et al. Naturally acquired Pneumocystis carinii pneumonia in gene disruption mutant mice: roles in distinct T-cell populations in infection. Infect Immun 1996; 64:3201-3209.
106. Furuta T, Fujita M, Machii K, et al. Fatal spontaneous pneumocystosis in nude rats. Lab Anim Sci 1993; 43:551-556.
107. Garvy BA, Harmsen AG. Susceptibility to Pneumocystis carinii infection: host responses of neonatal mice from immune or naive mothers and of immune or naive adults. Infect Immun 1996; 64:3987-3992.
108. Garvy BA, Qureshi MH. Delayed inflammatory response to Pneumocystis carinii infection in neonatal mice due to an inadequate lung environment. J Immunol 2000; 165:6480-6486.
109. Qureshi MH, Garvy BA. Neonatal T cells in an adult lung environment are competent to resolve Pneumocystis carinii pneumonia. J Immunol 2001; 166:5704-5711.
110. Phair J, Munoz A, Detels R, et al. The risk of Pneumocystis carinii pneumonia among men infected with immunodeficiency virus type 1. N Engl J Med 1990; 322:161-165.
111. Centers for disease control and prevention. Guidelines for preventing opportunistic infections among HIV-infected persons—2002 Recommendations of the U.S. Public Health Service and the Infectious Disease Society of America. MMWR 2002; 51((RR-8)):1-52.
112. Koziel H, Kim S, Reardon C, Li X, Garland R, Pinkston P, Kornfield H. Enhanced in vivo human immunodeficiency virus-1 replication in the lungs of human immunodeficiency virus-infected persons with Pneumocystis carinii pneumonia. Am J Respir Crit Care Med 1999; 160:2048-2055.
113. Agostini C, Adami F, Poulter LW, Israel-Biet D, Freitas e Costa M, Cipriani A, Sancetta R, Lipman MC, Juvin K, Teles-Araujo AD, Cadrobbi P, Masarotto G, Semenzato G. Role of bronchoalveolar lavage in predicting survival of patients with human immunodeficiency virus infection. Am J Respir Crit Care Med 1997; 156:1501-1507.
114. Kumar SD, Krieger BP. CD4 lymphocyte counts and mortality in AIDS patients requiring mechanical ventilator support due to Pneumocystis carinii pneumonia. Chest 1998; 113:430-433.
115. Mansharamani NG, Balachandran D, Vernofsky I, Garland R, Koziel H. peripheral blood CD4 T lymphocyte counts during Pneumocystis carinii pneumonia in immunocompromised patients without HIV infection. Chest 2000; 118:712-720.
116. Harmsen AG, Stankiewicz M. Requirement to CD4 + cells in resistance to Pneumocystis carinii pneumonia in mice. J Exp Med 1990; 172:937-945.
117. Shellito J, Suzara VV, Blumenfeld W, Beck JM, Steger HJ, Ermak TH. A new model of Pneumocystis carinii infection in mice selectively depleted of help T lymphocytes. J Clin Invest 1990; 85:1686-1693.
118. Shellito JE, Tate C, Ruan S, et al. Murine CD4+ T lymphocyte subsets and host defense against Pneumocystis carinii. J Infect Dis 2000; 181:2011-2017.
119. Levy J, Espanol-Boren T, Fischer ATC. Clinical spectrum of X-linked hyper-IgM syndrome. J Pediatr 1997; 131:47-54.
120. Wiley JA, Harmsen AG. CD 40 ligand is required for resolution of Pneumocystis carinii pneumonia in mice. J Immunol 1995; 155:3525-3259.
121. Walzer PD, LaBine M, Redington TJ, Cushion MT. Lymphocyte changes during chronic administration and withdrawal of corticosteroids: relevance to Pneumocystis carinii pneumonia. J Immunol 1984; 133:2502-2508.
122. Beck JM, Newbury RL, Palmer BE, Warnock WL, Byrd PK. Role of CD8 + lymphocytes in host defense against Pneumocystis carinii in mice. J Lab Clin Med 1996; 128:477-487.
123. Kolls JK, Habetz S, Shean MK, Vazquez C, Brown JA, Lei D, Schwarzenberger P, Ye P, Nelson S, Summer WR, Shellito JE. IFN-7 and CD8+ T cells restore host defenses against Pneumocystis carinii in mice depleted of CD4 + T cells. J Immunol 1999; 162:2890-2894.
124. Croix DA, Board K, Capuano S, Murphey-Corb M, Haidaris CG, Flynn JL, Reinhart T, Norris KA. Alterations in T lymphocyte profiles of bronchoalveolar lavage fluid from SIV- and Pneumocystis carinii-coinfected rhesus macaques. AIDS Res Hum Retrovir 2002; 18:391-401.
125. Jensen BN, Lisse IM, Gerstot J, et al. Cellular profiles in bronchoalveolar lavage fluid of HIV-infected patients with pulmonary symptoms: relation to diagnosis and prognosis. AIDS 1991; 5:527-533.
126. Semenzato G, Agostini C, Ometto L, Zambello R, Trentin L, Chieco-Bianchi L, De Rossi A. CD8 + T lymphocytes in the lung of acquired immunodeficiency syndrome patients harbor human immunodeficiency virus type 1. Blood 1995; 85: 2308-2314.
127. Forte M, Maartens G, Campbell F, Stubberfield C, Shahmanesh M, Kumararatne D, Gaston H. T-lymphocyte responses to Pneumocystis carinii in healthy and HIVpositive individuals. J AIDS 1992; 5:409-416.
128. Hagler DN, Deepe GS, Pogue CL, Walzer PD. Blastogenic responses to Pneumocystis carinii among patients with human immunodeficiency (HIV) infection. Clin Exp Immunol 1988; 74:7-13.
129. Herrod HG, Valenski WR, Woods DR, Pifer LL. The in vitro response of human lymphocytes to Pneumocystis carinii antigen. J Immunol 1981; 126:59-61.
130. Theus SA, Sawhney N, Smulian AG, Walzer PD. Proliferation and cytokine responses of human T lymphocytes isolated from HIV patients to the major surface glycoprotein of Pneumocystis carinii. J Infect Dis 1998; 177:238-241.
131. Li Pira G, Fenoglio D, Bottone L, Terranova P, Pontali E, Caroli F, Seri M, Cailliez J-C, Koopman G, Accolla R, Del Galdo F, Abbate G, De Palma R, Mancia F. Preservation of clonal heterogeneity of the Pneumocystis carinii-specific CD4 T cell repertoire in HIV infected, asymptomatic individuals. Clin Exp Immunol 2002; 128:155-162.
132. Limper AH, Hoyte JS, Standing JE. The role of alveolar macrophages in Pneumocystis carinii degradation and clearance from the lung. J Clin Invest 1997; 99: 2110-2117.
133. Koziel H, O’Riodan D, Warner A. Alveolar macrophage interaction with Pneumocystis carinii. Immunol Ser 1994; 60:417-436.
134. Beck JM, Warnock ML, Curtis JL, Sniezek MJ, Arraj-Peffer SM, Kaltreider HB, Shellito JE. Inflammatory responses to Pneumocystis carinii in mice selectively depleted of helper T lymphocytes. Am J Respir Cell Mol Biol 1991; 5:186-197.
135. Hanano R, Reifenberg K, Kaufmann SHE. Activated pulmonary macrophages are insufficient for resistance against Pneumocystis carinii. Infect Immun 1998; 66: 305-314.
136. Beck JM, Preston AM, Gyethko MR. Urokinase-type plasminogen activator in inflammatory cell recruitment and host defense against Pneumocystis carinii in mice. Infect Immun 1999; 67:879-884.
137. Fox D, Smulian AG. Plasminogen-binding activity of enolase in the opportunistic pathogen Pneumocystis carinii. Med Mycol 2001; 39:495-507.
138. Forte M, Rahelu M, Stubberfield C, et al. In-vitro interaction of human macrophages with Pneumocystis carinii. Int J Exp Pathol 1991; 72:589-598.
139. Laursen AL, Moller B, Rungby J, et al. Pneumocystis carinii-induced activation of the respiratory burst in human monocytes and macrophages. Clin Exp Immunol 1994; 98:196-202.
140. Vassallo R, Kottom TJ, Standing JE, et al. Vitronectin and fibronectin function as glucan binding proteins augmenting macrophage responses to Pneumocystis carinii. Am J Respir Cell Mol Biol 2001; 25:203-211.
141. Vassallo R, Standing JE, Limper AH. Isolated Pneumocystis carinii cell wall glucan provokes lower respiratory tract inflammatory responses. J Immunol 2000; 164: 3755-3763.
142. Shellito JE, Kolls JK, Olariu R, et al. Nitric oxide and host defense against Pneumocystis carinii infection in a mouse model. J Infect Dis 1996; 173:432-439.
143. Simonpoli AM, Rajagopalan-Levasseur P, Brun-Pascaud M, et al. Influence of Pneumocystis carinii on nitrite production by rat alveolar macrophages. J Eukaryot Microbiol 1996; 43:400-403.
144. Downing JF, Kachel DL, Pasula R, et al. Gamma interferon stimulates rat alveolar macrophages to kill Pneumocystis carinii by L-arginine and tumor necrosis factor-dependent mechanisms. Infect Immun 1999; 67:1347-1352.
145. Kandil O, Fishman JA, Koziel H, et al. Human immunodeficiency virus type 1 infection of human macrophages modulates the cytokine response to Pneumocystis carinii. Infect Immunol 1994; 62:644-650.
146. Koziel H, Eichbaum Q, Kruskal BA, et al. Reduced binding and phagocytosis of Pneumocystis carinii by alveolar macrophages from persons infected with HIV-1 correlates with mannose receptor downregulation. J Clin Invest 1998; 102: 1332-1344.
147. Fraser IP, Takahashi K, Koziel H, et al. Pneumocystis carinii enhance soluble mannose receptor production by macrophages. Microbes Infect 2000; 2:1305-1310.
148. Stehle SE, Rogers RA, Harmsen AG, et al. A soluble mannose receptor immunoadh-esin enhances phagocytosis of Pneumocystis carinii by human polymorphonuclear leukocytes in vitro. Scand J Immunol 2000; 52:131-137.
149. Chen W, Havell EA, Harmsen AG. Importance of endogenous tumor necrosis factor alpha and gamma interferon in host resistance against Pneumocystis carinii infection. Infect Immun 1992; 60:1279-1284.
150. Kolls JK, Dinghua L, Vazquez C, et al. Exacerbation of murine Pneumocystis carinii infection by adenoviral-mediated gene transfer of a TNF inhibitor. Am J Respir Cell Mol Biol 1997; 16:112-118.
151. Limper AH. Tumor necrosis factor a-mediated host defense against Pneumocystis carinii. Am J Respir Cell Mol Biol 1997; 16:110-111.
152. Chen W, Havell EA, Moldawer LL, et al. EA. Interleukin 1: an important mediator of host resistance against Pneumocystis carinii infection. J Exp Med 1992; 176: 713-718.
153. Pesanti EL. Interaction of cytokines and alveolar cells with Pneumocystis carinii in vitro. J Infect Dis 1994; 163:611-616.
154. Garvy BA, Ezekowitz RAB, Harmsen AG. Role of gamma interferon in the host immune and inflammatory responses to Pneumocystis carinii infection. Infect Immun 1997; 65:373-379.
155. Beck JM, Liggitt HD, Brunette EN, et al. Reduction in intensity of Pneumocystis carinii pneumonia in mice by aerosol administration of interferon-gamma. Infect Immun 1991; 59:3859-3862.
156. Shear HL, Valladares G, Narachi MA. Enhanced treatment of Pneumocystis carinii pneumonia in rats with interferon-7 and reduced doses of trimethoprim/sulfameth-oxazole. J AIDS 1990; 3:943-948.
157. Ishimine T, Kawakami K, Nakamoto A, et al. Analysis of cellular response and gamma interferon synthesis in bronchoalveolar lavage fluid and lung homogenate of mice infected with Pneumocystis carinii. Microbiol Immunol 1995; 39:49-58.
158. Mandujano JF, Nympha B, D’Sousa B, et al. Granulocyte-macrophage colony stimulating factor and Pneumocystis carinii pneumonia in mice. Am J Respir Care Med 1995; 151:1233-1238.
159. Paine R, Preston AM, Wilcoxen S, et al. Granulocyte-macrophage colony-stimulating factor in the innate immune response to Pneumocystis carinii pneumonia in mice. J Immunol 2000; 164:2602-2609.
160. Rudmann DG, Preston AM, Moore MW, et al. Susceptibility to Pneumocystis carinii in mice is dependent on simultaneous deletion of INF-7 and type 1 and 2 TNF receptor genes. J Immunol 1998; 161:360-366.
161. Chen W, Havell EA, Gigliotti F, et al. Interleukin-6 production in a murine model of Pneumocystis carinii pneumonia: relation to resistance and inflammatory response. Infect Immun 1992; 61:97-102.
162. Ruan S, Tate T, Lee JJ, et al. Local delivery of viral interleukin-10 gene suppresses tissue inflammation in murine Pneumocystis carinii infection. Infect Immun 2002; 70:6107-6113.
163. Quereshi MH, Garmsen AG, Garvey BA. IL-10 moculates host responses and lung damage induced by Pneumocystis carinii infection. J Immunol 2003; 170: 1002-1009.
164. Ikei R, Furuta T, Asano S. Effect of recombinant human granulocyte colony stimulating factor on Pneumocystis carinii infection in nude mice. Jpn J Exp Med 1989; 59:51-58.
165. Warschkau H, Yu H, Kiderlen AF. Activation and suppression of natural cellular immune functions by Pneumocystis carinii. Immunobiology 1998; 198:343-360.
166. Guzman J, Wang YM, Teschler H, et al. Phenotypic analysis of bronchoalveolar lavage lymphocytes from acquired immunodeficiency patients with and without Pneumocystis carinii pneumonia. Acta Cytol 1992; 36:900-904.
167. Duncan RA, Von Reyn CF, Alliegro GM, et al. Idiopathic CD4 T-lymphocytopenia: four patients with opportunistic infections and no evidence of HIV infection. N Eng J Med 1993; 328:393-398.
168. Bonagura VR, Cunningham-Rundles S, Edwards BL, et al. Common variable hypogammaglobulinemia, recurrent Pneumocystis carinii pneumonia on intravenous a-globulin therapy, and natural killer deficiency. Clin Immunol Immunopathal 1995; 51:216-223.
169. Bonagura VR, Cunningham-Rundles SL, Schuval S. Dysfunction of natural killer cells in human immunodeficiency virus-infected children with our without Pneumocystis carinii pneumonia. J Pediatr 1992; 121:195-201.
170. Laursen AL, Rungby J, Andersen PL. Decreased activation of the respiratory burst in neutrophils from AIDS patients with previous Pneumocystis carinii pneumonia. J Infect Dis 1995; 172:497-505.
171. Chen W, Mills JW, Harmsen AG. Development and resolution of Pneumocystis carinii pneumonia in severe combined immunodeficient mice: a morphological study of host inflammatory responses. Int J Exp Pathol 1992; 73:709-720.
172. Wright TW, Johnston CJ, Harmsen AG, et al. Analysis of cytokine mRNA profiles in the lungs of Pneumocystis carinii-infected mice. Am J Respir Cell Mol Biol 1997; 17:491-500.
173. Wright TW, Gigliotti F, Finkelstein JN, McBride JT, An CL, Harmsen AG. Immune mediated inflammation directly impairs pulmonary function contributing to the pathogenesis of Pneumocystis carinii pneumonia. >J Clin Invest 1999; 104: 1307-1317.
174. Wright TW, Johnston CJ, Harmsen AG, Finkelstein JN. Chemokine gene expression during Pneumocystis carinii-driven pulmonary inflammation. Infect Immun 1999; 67:3452-3460.
175. Wright TW, Notter RH, Wang Z, Harmsen AG, Gigliotti F. Pulmonary inflammation disrupts surfactant function during Pneumocystis carinii pneumonia. Infect Immun 2001; 69:758-764.
176. Hori S, Thiago L, Demengeot J. CD25 + regulatory T cells suppress CD4+ T cell-mediated pulmonary hyperinflammation driven by Pneumocystis carinii in immunodeficient mice. Eur J Iimmunol 2002; 32:1282-1291.
177. Thullen T, Daly K, Linke MJ, Ashbaugh A, Walzer PD. New rat model of Pneumocystis pneumonia induced by Anti-CD4 + T-lymphocyte antibodies. Infect Immun 2003; 71:6292-6297.
178. Perenboom RM, Beckers P, Van Der Meer JW, Van Schijndel AC, Oyen WJ, Corstens FH. Pro-inflammatory cytokines in lung and blood during steroid-induced Pneumocystis carinii pneumonia in rats. J Leukoc Biol 1996; 60:710-715.
179. Thullen T, Linke M, Daly K, Ashbaugh A, Walzer PD. Sensitized splenocytes results in deleferons cytokine cascade and hyperinflammatory response in rats with Pneumocytis pneumonia despite the presence of corticosteroids. Infect Immun 2004; 72:757-765.
180. Wislez M, Bergot E, Antione M, et al. Acute respiratory failure following HAART introduction in patients treated for Pneumocystis carinii pneumonia. Am J Respir Crit Cae Med 2001; 164:847-851.
181. Mason GR, Hashimoto CH, Dickman PS et al. Prognostic implications of brono-choalveolar lavage neutrophilia in patients with Pneumocystis carinii pneumonia and AIDS. Am Rev Respir Dis 1989; 139:1336-1342.
182. Limper AH, Offord KP, Smith TF, et al. Pneumocystis carinii pneumonia. Am Rev Respir Dis 1989; 140:1204-1209.
183. Benefield TL, Vestbo J, Junge J, et al. Prognostic value of interleukin-8 in AIDS-associated Pneumocystis carinii pneumonia. Am J Respir Crit Care Med 1995; 151: 1058-1062.
184. Benefield TL, van Steenwijk R, Nielsen TL, et al. Interleukin-8 and eicosanoid production in the lung during moderate to severe Pneumocystis carinii pneumonia in AIDS: a role of interleukin-8 in the pathogenesis of P. carinii pneumonia. Respir Med 1995; 89:285-290.
185. Lipschik GY, Doerfler ME, Kovacs JA, et al. Leukotriene B4 and interleukin-8 in human immunodeficiency virus-related pulmonary disease. Chest 1993; 104: 763-769.
186. Denis M, Ghadirian E. Dysregulatin of interleukin 8, interleukin 10, and interleukin 12 release by alveolar macrophages from HIV type 1-infected subjects. AIDS Res Hum Retrovir 1994; 10:1619-1627.
187. Villard J, Dayer-Pastore F, Hamacher J, et al. GRO alpha and interleukin-8 in Pneumocystis carinii or bacterial pneumonia and adulty respiratory distress syndrome. Am J Respir Crit Care Med 1995; 152:1549-1554.
188. Benfield TL, Kharazmi A, Larsen CG, et al. Neutrophil chemotactic activity in bronchoalveolar lavage fluid of patients with AIDS-associated Pneumocystis carinii pneumonia. Scand J Infect Dis 1997; 29:367-371.
189. Benfield TL, Lundgren B, Levine SJ, et al. The major surface glycoprotein of Pneumocystis carinii induces release and gene expression of interleukin-8 and tumor necrosis factor alpha in monocytes. Infect Immun 1997; 65:4790-4794.
190. Krishnan VL, Meager A, Mitchell DM, et al. Alveolar macrophages in AIDS patients: increased spontaneous tumour necrosis factor-alpha production in Pneumocystis carinii pneumonia. Clin Exp Immunol 1990; 80:156-160.
191. Millar AB, Miller RF, Foley NM, et al. Production of tumor necrosis factor-alpha by blood and lung mononuclear phagocytes from patients with human immunodeficiency virus-related lung disease. Am J Respir Cell Mol Biol 1991; 5:144-148.
192. Huang ZB, Eden E. Effect of corticosteroids on IL1 beta and TNF alpha releaseby alveolar macrophages from patients with AIDS and Pneumocystis carinii pneumonia. Chest 1993; 104:751-755.
193. Benfield TL, Lundgren B, Shelhamer JH, et al. Pneumocystis carinii major surface glycoprotein induces interleukin-8 and monocyte chemoattractant protein-1 release from a human alveolar epithelial cell line. Eur J Clin Invest 1999; 29:717-722.
194. De Benedetti E, Nicod L, Reber G, et al. Procoagulant and fibrinolytic activities in bronchoalveolar fluid of HIV-positive and HIV-negative patients. Eur Respir J 1992; 5:411-417.
195. Angelici E, Contini C, Romani R, et al. Production of plasminogen activator and plasminogen activator inhibitors by alveolar macrophages in control subjects and AIDS patients. AIDS 1996; 10:283-290.
196. Benfield TL, Schattenkerk JK, Hofmann B, et al. Differential effect on serum neopterin and serum beta 2-microglobulin is induced by treatment in Pneumocystis carinii pneumonia. J Infect Dis 1994; 169:1170-1173.
197. Perenboom RM, Sauerwein RW, Beckers P, van Schijndel AC, van Steenwijk RP, Borleffs JC. Cytokine profiles in bronchoalveolar lavage fluid and blood in HIV-seropositive patients with Pneumocystis carinii pneumonia. Eur J Clin Invest 1997; 27:333-339.
198. Perenboom RM, van Schijndel AC, Beckers P, Sauerwein R, Van Hamersvelt HW, Festen J, Gallati H, van der Meer JW. Cytokine profiles in bronchoalveolar lavage fluid and blood in HIV-seronegative patients with Pneumocystis carinii pneumonia. Eur J Clin Invest 1996; 26:159-166.
199. The National Institutes of Health-University of California Expert Panel for Corticosteroids as Adjunctive Therapy for Pneumocystis carinii Pneumonia. Consensus statement on the use of corticosteroids as adjunctive therapy for Pneumocystis pneumonia in the acquired immunodeficiency syndrome. N Engl J Med 1990; 323: 1500-1504.
200. Hoffman AGD, Lawrence MG, Ognibene FP. Reduction of pulmonary surfactant in patients with human immunodeficiency virus and Pneumocystis carinii pneumonia. Chest 1992; 102:1730-1736.
201. 2 in experimental Pneumocystis carinii pneumonia. Am Rev Respir Dis 1986; 134:526-531.
202. Su TH, Natarajan V, Kachel DL. Functional impairment of bronchoalveolar lavage phospholipids in early Pneumocystis carinii pneumonia in rats. J Lab Clin Med 1996; 127:263-271.
203. Atochina EN, Beers MF, Scanlon ST, et al. P. carinii induces selective alterations in component expression and biophysical activity of lung surfactant. Am J Physiol Lung Cell Mol Physiol 2000; 278:L599-L609.
204. Atochina EN, Beck JM, Scanlon ST, et al. Pneumocystis carinii pneumonia alters expression and distribution of lung collectins SP-A and SP-D. J Lab Clin Med 2001; 137:429-439.
205. Beers MF, Atochina EN, Preston AM, et al. Inhibition of lung surfactant protein B expression during Pneumocystis carinii pneumonia in mice. J Lab Clin Med 1999; 133:406-407.
206. Steinberg RI, Whitsett JA, Hull WM, et al. Pneumocystis carinii alters surfactant protein A concentrations in bronchoalveolar lavage fluid. J Lab Clin Med 1995; 125:462-469.
207. Rice WR, Singleton FM, Linke MJ, et al. Regulation of surfactant phosphatidycho-line secretion from alveolar type II cells during Pneumocystis carinii pneumonia in the rat. J Clin Invest 1993; 92:2778-2882.
208. Lipschik GY, Treml JF, Moore SD et al, Pneumocystis carinii glycoprotein A inhibits surfactant phospholipid secretion by rat alveolar type II cells. J Infect Dis 1998; 177:182-187.
209. Dichter JR, Lundgren JD, Nielsen TL, et al. Pneumocystis carinii pneumonia in H-infected patients: effect of steroid therapy on surfactant level. Respir Med 1999; 93:373-378.